

病態分子イメージングセンターに係る業績

講座等名	iPS・幹細胞再生医学講座	事業推進者名	人見 浩史
<雑誌論文>			
1. Yamashita H, Fukuda K, <u>Hattori F</u> . Hepatocyte-like cells derived from human pluripotent stem cells can be enriched by combination of mitochondrial content and activated leukocyte cell adhesion molecule. JMA Journal. レフェリー有, 2019 in press.			
2. Tamaki H, Ikegame K, Yoshihara S, Kaida K, Yoshihara K, Inoue T, Kato R, Nakata J, <u>Fujioka T</u> , Soma T, Okada M, Ogawa H. Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft-vs-host disease prophylaxis compared with cord blood transplantation. Transplant Infectious Disease. レフェリー有, e13073, 2019			
3. <u>Matsuoka Y</u> , <u>Sumide K</u> , <u>Sonoda Y</u> . One-year Observation of the SCID-repopulating Cell Activities of Human Cord Blood-derived CD34-positive and -negative Hematopoietic Stem Cells. Stem Cell Reviews and Reports. レフェリー有, 2019 in press.			
4. <u>松岡 由和</u> , <u>藺田 精昭</u> . ヒト臍帯血由来造血幹細胞の陽性分子マーカーとしての GPI-80 抗原の有有用性。Cytometry Research. レフェリー有, 228:13-17, 2018.			
5. <u>Matsuoka Y</u> , Nakamura F, Hatanaka K, <u>Fujioka T</u> , Otani S, Kimura T, Fujimura Y, Asano H, <u>Sonoda Y</u> . The number of CD34 <sup>+</sup> CD133 <sup>+</sup> hematopoietic stem cell residing in umbilical cord blood units is not correlated with the number of total nucleated cells and CD34 <sup>+</sup> cells: A possible new indicator for quality evaluation of UCB units. International Journal of Hematology. レフェリー有, 108:571-9, 2018			
6. <u>Sumide K</u> , <u>Matsuoka Y</u> , Kawamura H, <u>Nakatsuka R</u> , <u>Fujioka T</u> , Asano H, Takihara Y, <u>Sonoda Y</u> . A Revised Road Map for the Commitment of Human Cord Blood CD34-negative Hematopoietic Stem Cells. Nature Communications レフェリー有, 9:2202, 2018.			
7. Kawamura H, <u>Nakatsuka R</u> , <u>Matsuoka Y</u> , <u>Sumide K</u> , <u>Fujioka T</u> , Asano H, <u>Sonoda Y</u> . TGF- $\beta$ Signaling Accelerates Senescence of Human Bone-Derived CD271 and SSEA-4 Double-Positive Mesenchymal Stromal Cells. Stem Cell Reports レフェリー有, 10:920-32, 2018.			
8. Zhang Y, Nakano D, Guan Y, <u>Hitomi H</u> , Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney International レフェリー有, 94:524-35, 2018.			
9. Wan N, Rahman A, <u>Hitomi H</u> , Nishiyama A. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. Frontiers in Endocrinology レフェリー有, 26:9:421, 2018.			
10. Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, <u>Hitomi H</u> , Kobori H, Nishiyama A. Effects of an SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotaly nephrectomized rats. Journal of Pharmacological Sciences レフェリー有, 137:220-3, 2018.			
11. Rahman A, Yamazaki D, Sufiun A, Kitada K, <u>Hitomi H</u> , Nakano D, Nishiyama A. A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLoS One レフェリー有, 13:e0192531, 2018.			
12. Yamazaki D, <u>Hitomi H</u> , Nishiyama A. Hypertension with diabetes mellitus "Complications". Hypertension Research レフェリー有, 41:147-56, 2018.			
13. Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, <u>Hitomi H</u> , Kobori H, Nishiyama A. Effects of an SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotaly nephrectomized rats. Journal of Pharmacological Sciences レフェリー有, 137: 220-3, 2018.			
14. Park SH, Uzawa T, <u>Hattori F</u> , Ogino S, Morimoto N, Tsuneda S, Ito Y. "All-in-one" in vitro selection of collagen-binding vascular endothelial growth factor. Biomaterials レフェリー有, 6:270-278, 2018.			
15. <u>Matsuoka Y</u> , Takahashi M, <u>Sumide K</u> , Kawamura H, <u>Nakatsuka R</u> , <u>Fujioka T</u> , <u>Sonoda Y</u> . CD34 Antigen and the MPL Receptor Expression Defines A Novel Class of Human Cord Blood-Derived Primitive Hematopoietic Stem Cells. Cell Transplant レフェリー有, 26:1043-1058, 2017.			
16. <u>Sonoda Y</u> . Human Hematopoietic Stem Cells: The Current Understanding and Future Prospects. Journal of Hematopoietic Cell Transplantation レフェリー有, 6:70-83, 2017.			
17. <u>Hitomi H</u> , Kasahara T, Katagiri N, Hoshina A, Mae S, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa A, Saito M, Nakahata T, Nishiyama A, Osafune K. Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice. Science Translational Medicine レフェリー			

一有, 9:409, 2017.

18. Ansary TM, Fujisawa Y, Rahman A, Nakano D, Hitomi H, Kobara H, Masaki T, Titze JM, Kitada K, Nishiyama A. Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. *Scientific Reports* レフェリー有, 7:9555, 2017.
19. Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. *Clinical and Experimental Pharmacology and Physiology* レフェリー有, 44:522-5, 2017.
20. Hasan AU, Kittikulsuth W, Yamaguchi F, Ansary TM, Rahman A, Shibayama Y, Nakano D, Hitomi H, Tokuda M, Nishiyama A. IBMX protects human proximal tubular epithelial cells from hypoxic stress through suppressing hypoxia-inducible factor-1 $\alpha$  expression. *Experimental Cell Research* レフェリー有, 358:343-51, 2017.
21. Guan Y, Nakano D, Zhang Y, Li L, Liu W, Nishida M, Kuwabara T, Morishita A, Hitomi H, Mori K, Mukoyama M, Masaki T, Hirano K, Nishiyama A. A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy. *Journal of Pharmacological Sciences* レフェリー有, 135:81-8, 2017.
22. Miyashita T, Inamoto R, Fukuda S, Hoshikawa H, Hitomi H, Kiyomoto H, Nishiyama A, Mori N. Hormonal changes following a low-salt diet in patients with Ménière's disease. *Auris Nasus Larynx* レフェリー有, 44:52-7, 2017.
23. Rahman A, Hitomi H, Nishiyama A. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. *Hypertension Research* レフェリー有, 40:535-40, 2017.
24. Hitomi H, Nishiyama A. How should we treat patients with primary aldosteronism to prevent new-onset diabetes mellitus? *Journal of Hypertensions*. レフェリー有, 35:1575-6, 2017.

<学会発表>

1. 松岡由和, 角出啓輔, 中塚隆介, 白水泰昌, 藤岡龍哉, 藪田精昭, 服部文幸, 人見浩史. CRISPR/Cas9 システムを用いたヒト造血幹細胞における CD34 抗原の発現意義の解析. 第 18 回日本再生医療学会総会, 神戸市, 2019 年 3 月 21 日
2. 人見浩史. iPS 細胞由来細胞を用いた腎臓・内分泌領域創薬の新展開, 第 92 回日本薬理学会年会, 大阪市, 2019 年 3 月 14 日
3. 松岡由和, 中塚隆介, 藤岡龍哉. 機械学習による血球細胞の自動判別システム. 第 80 回日本血液学会, 大阪市, 2018 年 10 月 13 日
4. 藪田精昭. ヒト造血幹細胞の最新知見-ヒト造血幹細胞の純化と階層制の解明-第 80 回日本血液学会, 大阪市, 2018 年 10 月 12 日
5. 人見浩史. iPS 細胞を用いた慢性腎不全の次世代治療法, 第 48 回日本腎臓学会西部学術大会, 徳島市, 2018 年 9 月 28 日
6. 松岡由和. Automatic discrimination system for hematopoietic tumor-derived cell lines using Machine Learning. 第 77 回日本癌学会, 大阪市, 2018 年 9 月 27 日
7. 人見浩史, 西山成, 長船健二. iPS 細胞を用いて腎性貧血を治療する, 第 63 回日本透析医学会学術集会, 神戸市, 2018 年 6 月 30 日
8. 人見浩史, 笠原朋子, 片桐直子, 保科あずさ, 前伸一, 小高真希, 豊原敬文, Asadur Rahman, 中野大介, 丹羽明, 斎藤潤, 中畑龍俊, 西山成, 長船健二. iPS 細胞由来エリスロポエチン産生細胞を用いた腎性貧血に対する細胞療法開発, 第 61 回日本腎臓学会学術総会, 新潟市, 2018 年 6 月 10 日
9. 松岡由和, 角出啓輔, 中塚隆介, 藤岡龍哉, 藪田精昭. 重症免疫不全マウスにおける継代移植を用いないヒト造血幹細胞活性の長期解析. 第 28 回日本サイトメトリー学会, 東京都, 2018 年 5 月 26 日
10. Hirofumi Hitomi, Daisuke Nakano, Kenji Osafune, Akira Nishiyama. Human pluripotent stem cell-derived erythropoietin-producing cells improve renal anemia in mice, WCP2018, Kyoto, Japan, 2018 年 7 月 4 日
11. Hirofumi Hitomi, Tomoko Kasahara, Naoko Katagiri, Azusa Hoshina, Shin-Ichi Mae, Maki Kotaka, Takafumi Toyohara, Asadur Rahman, Daisuke Nakano, Akira Niwa, Megumu K. Saito, Tatsutoshi Nakahata, Akira Nishiyama, Kenji Osafune. Human pluripotent stem cell-derived erythropoietin-producing cells improve renal anemia in mice, ISSCR 2018 Annual Meeting, Melbourne, Australia, 2018 年 6 月 21 日